IBDEI0QB ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,12983,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,12983,1,4,0)
 ;;=4^205.11
 ;;^UTILITY(U,$J,358.3,12983,1,5,0)
 ;;=5^CML in Remission
 ;;^UTILITY(U,$J,358.3,12983,2)
 ;;=^267534
 ;;^UTILITY(U,$J,358.3,12984,0)
 ;;=238.4^^87^827^61
 ;;^UTILITY(U,$J,358.3,12984,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,12984,1,4,0)
 ;;=4^238.4
 ;;^UTILITY(U,$J,358.3,12984,1,5,0)
 ;;=5^Polycythemia Vera
 ;;^UTILITY(U,$J,358.3,12984,2)
 ;;=^96105
 ;;^UTILITY(U,$J,358.3,12985,0)
 ;;=238.79^^87^827^45
 ;;^UTILITY(U,$J,358.3,12985,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,12985,1,4,0)
 ;;=4^238.79
 ;;^UTILITY(U,$J,358.3,12985,1,5,0)
 ;;=5^Lymph/Hematopoietic Tis NEC
 ;;^UTILITY(U,$J,358.3,12985,2)
 ;;=^334033
 ;;^UTILITY(U,$J,358.3,12986,0)
 ;;=287.30^^87^827^62
 ;;^UTILITY(U,$J,358.3,12986,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,12986,1,4,0)
 ;;=4^287.30
 ;;^UTILITY(U,$J,358.3,12986,1,5,0)
 ;;=5^Primary Thrombocytopenia
 ;;^UTILITY(U,$J,358.3,12986,2)
 ;;=^332841
 ;;^UTILITY(U,$J,358.3,12987,0)
 ;;=202.40^^87^827^41
 ;;^UTILITY(U,$J,358.3,12987,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,12987,1,4,0)
 ;;=4^202.40
 ;;^UTILITY(U,$J,358.3,12987,1,5,0)
 ;;=5^Hairy Cell Leukemia,Unspecified site
 ;;^UTILITY(U,$J,358.3,12987,2)
 ;;=^69587
 ;;^UTILITY(U,$J,358.3,12988,0)
 ;;=173.91^^87^827^6
 ;;^UTILITY(U,$J,358.3,12988,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,12988,1,4,0)
 ;;=4^173.91
 ;;^UTILITY(U,$J,358.3,12988,1,5,0)
 ;;=5^Basal Cell CA Skin,Site Unspec
 ;;^UTILITY(U,$J,358.3,12988,2)
 ;;=^340491
 ;;^UTILITY(U,$J,358.3,12989,0)
 ;;=160.9^^87^827^19
 ;;^UTILITY(U,$J,358.3,12989,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,12989,1,4,0)
 ;;=4^160.9
 ;;^UTILITY(U,$J,358.3,12989,1,5,0)
 ;;=5^Ca Accessory Sinuses
 ;;^UTILITY(U,$J,358.3,12989,2)
 ;;=^267127
 ;;^UTILITY(U,$J,358.3,12990,0)
 ;;=211.3^^87^827^40
 ;;^UTILITY(U,$J,358.3,12990,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,12990,1,4,0)
 ;;=4^211.3
 ;;^UTILITY(U,$J,358.3,12990,1,5,0)
 ;;=5^Colon Polyps (Current)
 ;;^UTILITY(U,$J,358.3,12990,2)
 ;;=^13295
 ;;^UTILITY(U,$J,358.3,12991,0)
 ;;=214.9^^87^827^44
 ;;^UTILITY(U,$J,358.3,12991,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,12991,1,4,0)
 ;;=4^214.9
 ;;^UTILITY(U,$J,358.3,12991,1,5,0)
 ;;=5^Lipoma NOS
 ;;^UTILITY(U,$J,358.3,12991,2)
 ;;=^71155
 ;;^UTILITY(U,$J,358.3,12992,0)
 ;;=185.^^87^827^49
 ;;^UTILITY(U,$J,358.3,12992,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,12992,1,4,0)
 ;;=4^185.
 ;;^UTILITY(U,$J,358.3,12992,1,5,0)
 ;;=5^Mal Neo Prostate
 ;;^UTILITY(U,$J,358.3,12992,2)
 ;;=^99481
 ;;^UTILITY(U,$J,358.3,12993,0)
 ;;=173.90^^87^827^50
 ;;^UTILITY(U,$J,358.3,12993,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,12993,1,4,0)
 ;;=4^173.90
 ;;^UTILITY(U,$J,358.3,12993,1,5,0)
 ;;=5^Mal Neo Skin,Unspec/Site Unspec
 ;;^UTILITY(U,$J,358.3,12993,2)
 ;;=^340605
 ;;^UTILITY(U,$J,358.3,12994,0)
 ;;=173.92^^87^827^69
 ;;^UTILITY(U,$J,358.3,12994,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,12994,1,4,0)
 ;;=4^173.92
 ;;^UTILITY(U,$J,358.3,12994,1,5,0)
 ;;=5^Squam Cell CA Skin,Site Unspec
 ;;^UTILITY(U,$J,358.3,12994,2)
 ;;=^340492
 ;;^UTILITY(U,$J,358.3,12995,0)
 ;;=218.9^^87^827^71
 ;;^UTILITY(U,$J,358.3,12995,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,12995,1,4,0)
 ;;=4^218.9
 ;;^UTILITY(U,$J,358.3,12995,1,5,0)
 ;;=5^Uterine Fibroids
 ;;^UTILITY(U,$J,358.3,12995,2)
 ;;=^68944
 ;;^UTILITY(U,$J,358.3,12996,0)
 ;;=112.1^^87^828^42
 ;;^UTILITY(U,$J,358.3,12996,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,12996,1,4,0)
 ;;=4^112.1
 ;;^UTILITY(U,$J,358.3,12996,1,5,0)
 ;;=5^Vulvovaginitis,Candidal
